Comparative study of long-term effects of atorvastatin and rosuvastatin on fasting glucose and hemoglobin A1c in patients with cardiovascular diseases
Open Access
- 9 October 2023
- journal article
- research article
- Published by University of Sarajevo Faculty of Health Sciences in Journal of Health Sciences
Abstract
Introduction: Statins are lipid lowering medications, used for the prevention of cardiovascular diseases (CVD), but have shown to increase the risk of Type 2 diabetes mellitus. The aim of this study was to investigate the effects of high-potency statins, atorvastatin, and rosuvastatin on fasting glucose (FG) and hemoglobin A1c (HbA1c) in CVD patients. Methods: The case–control study included 123 patients from Tuzla Canton, Bosnia, and Herzegovina, with a diagnosis of CVD, treated in three health centers: Public Health Center Gračanica, Banovići, and Čelić. Of total patients, 84 were statin users (39 atorvastatin users and 45 rosuvastatin users) and 39 were not. Demographic data, diagnosis, and data of the therapy were taken from the medical records, as well as data of the FG and HbA1c, measured before or within 3 months of the statin therapy introduction. For the same patients, FG and HbA1c were also measured at least 3 months after the introduction of therapy. Results: Obtained results have shown a significant increase of FG in CVD patients on statin therapy in relation to control (p = 0.034). Comparing the diabetogenic effects of atrovastatin and rosuvastatin, it was found that the HbA1c in patients on atorvastatin therapy was significantly higher comparing to those on rosuvastatain therapy (p = 0.028). The FG was significantly increased (p = 0.027) after atrovastatin therapy. Similar results were obtained in diabetogenic CVD patients, where HbA1c on atorvastatin therapy was significantly higher comparing to HbA1c in those on rosuvastatain therapy (p = 0.039). A significant correlation was found between the increase in FG and HbA1c with the duration of atorvastatin therapy (p = 0.001 and p = 0.033), and between the increase in HbA1c and the duration of rosuvastatin therapy (p = 0.001). Conclusion: Long-term therapy with high-potency statins, atorvastatin, and rosuvastatin, may increase levels of FG and HbA1c in patients with CVD, where atorvastatin shows more significant effects.Keywords
This publication has 29 references indexed in Scilit:
- Effects of statin therapy on glycemic control and insulin resistance: A systematic review and meta-analysisEuropean Journal of Pharmacology, 2023
- Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic miceNature Communications, 2023
- Differences in the diabetogenic effect of statins in patients with prediabetes. The PRELIPID studyMedicina Clinica, 2022
- Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA StudyAmerican Journal of Cardiovascular Drugs, 2016
- Drug‐Induced Diabetes Mellitus: Evidence for Statins and Other Drugs Affecting Glucose MetabolismClinical Pharmacology & Therapeutics, 2015
- Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysisDiabetologia, 2014
- The use of statins in people at risk of developing diabetes mellitus: Evidence and guidance for clinical practiceAtherosclerosis Supplements, 2014
- Statins and All-Cause Mortality in High-Risk Primary PreventionArchives of internal medicine (1960), 2010
- Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug–drug interactions and interindividual differences in transporter and metabolic enzyme functionsPharmacology & Therapeutics, 2006
- Intermolecular Differences of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Contribute to Distinct Pharmacologic and Pleiotropic ActionsThe American Journal of Cardiology, 2005